| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a2ea950ec2bf74cad94824b45ae93de5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03eebef0b6ee04c6f3ed37a1a03193e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_743d0c0f1d8a582aa36c2e5c621e94e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a6f489ba4668d3ce04b8388d22a141bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d3e8a2cda697e6f18652e235afdbc002 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55544
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 |
| filingDate |
2005-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f6b3fc1aa8ce79e8f25862034c16007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bce48081793f013f63bb4f0c2082a160
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f9394d986ff98ca9d1586d031ce60a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54ae29884da4a0577cdc213f90fda3f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8165d676b1d5f39a11f79f721ede27e6 |
| publicationDate |
2007-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1767214-A1 |
| titleOfInvention |
Use of neurotrophil activating protein of helicobacter pylori (HP-NAP) and/or of its portions as adjuvants for the development of T helper type 1 (TH1) immune responses |
| abstract |
Methods for modifying the quality of the T helper cell immune responses specific for antigens or allergens taking advantage of the Th1-promoting adjuvant effect of the Neutrophil Activating Protein (HP-NAP) of Helicobacter pylori. The adjuvant effect of HP-NAP protein is susceptible of therapeutic use in setting up vaccines or immunopotentiating strategies aimed to elicit Th1-type immune responses and/or to inhibit undesired Th2- or Th0-type immune responses. Clinical applications of the HP-NAP adjuvant effect for Th1 cell responses are: a) inhibition of immunopathogenic or undesired responses of Th0/Th2 type, b) potentiation of weak natural Th1 responses, that per se are unable to exert protection against pathogens or tumors. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018050225-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7901907-B2 |
| priorityDate |
2005-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |